基本信息
浏览量:82
职业迁徙
个人简介
An internationally recognized diabetes researcher, Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the director of the NIH. In addition, he had been a standing member of the American Diabetes Association, American Heart Association and NIH grant review committees. In 2011, he won the Dean’s Outstanding Faculty Award at EVMS, and in 2013, he was appointed by the Governor’s office of the Commonwealth of Virginia to sit on the Planning and Oversight Committee of the new Virginia Biosciences Health Research Corporation. Based on his excellence in research, he was elected to the American Society of Clinical Investigation.
Dr. Nadler’s groundbreaking contributions—which focus on understanding cardiovascular complications of diabetes and obesity—include his work in identifying inflammatory pathways leading to pancreatic beta cell damage, insulin resistance and atherosclerosis. Toward this end, his research has led to the development of preventative therapies and the identification of new small molecules blocking 12-Lipoxygenase activity. He has research funding from the NIH as well as the Juvenile Diabetes Foundation and his current work is designed to determine whether a virus could be a trigger for Type 1 diabetes.
As a prominent voice in his field, he has authored more than 200 peer-reviewed publications and has been an invited speaker at major international conferences, including the American Diabetes Association, Australian Diabetes Association, World Diabetes Congress and International Meetings of the European Association of Diabetes.
Additionally, as a leader in biomedical innovation, Dr. Nadler holds a number of patents for biomarkers and novel therapeutics. His clinical interest is focused on treatment and prevention of diabetes and related complications.
Dr. Nadler’s groundbreaking contributions—which focus on understanding cardiovascular complications of diabetes and obesity—include his work in identifying inflammatory pathways leading to pancreatic beta cell damage, insulin resistance and atherosclerosis. Toward this end, his research has led to the development of preventative therapies and the identification of new small molecules blocking 12-Lipoxygenase activity. He has research funding from the NIH as well as the Juvenile Diabetes Foundation and his current work is designed to determine whether a virus could be a trigger for Type 1 diabetes.
As a prominent voice in his field, he has authored more than 200 peer-reviewed publications and has been an invited speaker at major international conferences, including the American Diabetes Association, Australian Diabetes Association, World Diabetes Congress and International Meetings of the European Association of Diabetes.
Additionally, as a leader in biomedical innovation, Dr. Nadler holds a number of patents for biomarkers and novel therapeutics. His clinical interest is focused on treatment and prevention of diabetes and related complications.
研究兴趣
论文共 285 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
British journal of pharmacologyno. 20 (2023): 2677-2693
biorxiv(2023)
medRxiv : the preprint server for health sciences (2023)
引用156浏览0引用
156
0
Cell Reportsno. 13 (2022): 111011-111011
European heart journal openno. 3 (2022)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn